**** SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS ****
+----------------+--------------------------------------+----------+-----------+
| CAS# | Chemical Name | % | EINECS# |
|----------------|--------------------------------------|----------|-----------|
|----------------|--------------------------------------|----------|-----------|
| 50-07-7 |Mitomycin C | 4 | 200-008-6 |
|----------------|--------------------------------------|----------|-----------|
| 7647-14-5 |Sodium chloride | Balance | 231-598-3 |
+----------------+--------------------------------------+----------+-----------+
Text for R-phrases: see Section 16
Hazard Symbols: T
Risk Phrases: 25 33
**** SECTION 3 - HAZARDS IDENTIFICATION ****
EMERGENCY OVERVIEW
Toxic if swallowed. Danger of cumulative effects.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
Harmful if swallowed. May cause liver damage. May cause digestive
tract disturbances. May cause bone marrow depression.
Inhalation:
May cause respiratory tract irritation. May cause effects similar to
those described for ingestion. May cause pulmonary fibrosis and
permanent damage.
Chronic:
May cause cancer according to animal studies. Chronic exposure may
cause liver damage. Adverse reproductive effects have been reported
in animals. Potential cancer hazard.
**** SECTION 4 - FIRST AID MEASURES ****
Eyes:
Flush eyes with plenty of water for at least 15 minutes,
occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15
minutes while removing contaminated clothing and shoes. Wash clothing
before reuse.
Ingestion:
Do not induce vomiting. If victim is conscious and alert, give 2-4
cupfuls of milk or water. Never give anything by mouth to an
unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not
breathing, give artificial respiration. If breathing is difficult,
give oxygen. Get medical aid. Do NOT use mouth-to-mouth
resuscitation.
Notes to Physician:
**** SECTION 5 - FIRE FIGHTING MEASURES ****
General Information:
As in any fire, wear a self-contained breathing apparatus in
pressure-demand, MSHA/NIOSH (approved or equivalent), and full
protective gear. During a fire, irritating and highly toxic gases
may be generated by thermal decomposition or combustion.
Non-combustible, substance itself does not burn but may decompose
upon heating to produce irritating, corrosive and/or toxic fumes.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or
alcohol-resistant foam. Substance is noncombustible; use agent most
appropriate to extinguish surrounding fire.
**** SECTION 6 - ACCIDENTAL RELEASE MEASURES ****
General Information: Use proper personal protective equipment as indicated
in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective
Equipment section. Sweep up, then place into a suitable container for
disposal. Avoid generating dusty conditions. Provide ventilation.
**** SECTION 7 - HANDLING and STORAGE ****
Handling:
Wash thoroughly after handling. Remove contaminated clothing and
wash before reuse. Use only in a well-ventilated area. Minimize dust
generation and accumulation. Do not get in eyes, on skin, or on
clothing. Keep container tightly closed. Do not ingest or inhale.
Storage:
Do not store in direct sunlight. Keep container closed when not in
use. Store in a cool, dry, well-ventilated area away from
incompatible substances. Hormones and antibiotics room. Store below
40C.
**** SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION ****
Engineering Controls:
Facilities storing or utilizing this material should be equipped
with an eyewash facility and a safety shower. Use adequate general or
local exhaust ventilation to keep airborne concentrations below the
permissible exposure limits.
Exposure Limits
CAS# 50-07-7:
CAS# 7647-14-5:
Russia: 5 mg/m3 TWA
Personal Protective Equipment
Eyes:
Wear safety glasses and chemical goggles if splashing
is possible.
Skin:
Wear appropriate protective gloves and clothing to
prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize
contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29
CFR 1910.134 and ANSI Z88.2 requirements or European
Standard EN 149 must be followed whenever workplace
conditions warrant respirator use.
**** SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES ****
Physical State: Crystalline powder
Color: blue-violet
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 360 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble
Specific Gravity/Density:
Molecular Formula: C15H18N4O5
Molecular Weight: 334.32
**** SECTION 10 - STABILITY AND REACTIVITY ****
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, dust generation, excess heat,
temperatures above 40C.
Incompatibilities with Other Materials:
Strong oxidizing agents - strong acids - strong bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.
**** SECTION 11 - TOXICOLOGICAL INFORMATION ****
RTECS#:
CAS# 50-07-7: CN0700000
CAS# 7647-14-5: VZ4725000
LD50/LC50:
CAS# 50-07-7: Oral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30
mg/kg.
CAS# 7647-14-5: Draize test, rabbit, eye: 100 mg Mild; Draize test,
rabbit, eye: 100 mg/24H Moderate; Draize test, rabbit, eye: 10 mg
Moderate; Draize test, rabbit, skin: 50 mg/24H Mild; Draize test,
rabbit, skin: 500 mg/24H Mild; Inhalation, rat: LC50 = >42 gm/m3/1H;
Oral, mouse: LD50 = 4 gm/kg; Oral, rat: LD50 = 3000 mg/kg; Skin,
rabbit: LD50 = >10 gm/kg.
Carcinogenicity:
Mitomycin C -
California: carcinogen, initial date 4/1/88
IARC: Group 2B carcinogen
Sodium chloride -
Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.
**** SECTION 12 - ECOLOGICAL INFORMATION ****
**** SECTION 13 - DISPOSAL CONSIDERATIONS ****
Dispose of in a manner consistent with federal, state, and local regulations.
**** SECTION 14 - TRANSPORT INFORMATION ****
IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: II
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: II
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: II
USA RQ: CAS# 50-07-7: 10 lb final RQ; 4.54 kg final RQ
**** SECTION 15 - REGULATORY INFORMATION ****
European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T
Risk Phrases:
R 25 Toxic if swallowed.
R 33 Danger of cumulative effects.
Safety Phrases:
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 50-07-7: 3
CAS# 7647-14-5: 0
Canada
CAS# 50-07-7 is listed on Canada's NDSL List.
CAS# 7647-14-5 is listed on Canada's DSL List.
CAS# 50-07-7 is not listed on Canada's Ingredient Disclosure List.
CAS# 7647-14-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 50-07-7 is listed on the TSCA inventory.
CAS# 7647-14-5 is listed on the TSCA inventory.
**** SECTION 16 - ADDITIONAL INFORMATION ****
Text for R-phrases from Section 2
MSDS Creation Date: 2/02/1998 Revision #4 Date: 3/18/2003
The information above is believed to be accurate and represents the best
information currently available to us. However, we make no warranty of
merchantability or any other warranty, express or implied, with respect to
such information, and we assume no liability resulting from its use. Users
should make their own investigations to determine the suitability of the
information for their particular purposes. In no way shall the company be
liable for any claims, losses, or damages of any third party or for lost
profits or any special, indirect, incidental, consequential or exemplary
damages, howsoever arising, even if the company has been advised of
the possibility of such damages.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
|
|
|
| ALL MSDS PAGES IN THIS GROUP
| | NAME | CAS |
|
Piperonal, 99%
| 120-57-0 |
|
5-Chlorouracil, 99%
| 1820-81-1 |
|
Benzáa??anthracene-7,12-dione, 97% (uv-vis)
| 2498-66-0 |
|
(3,4-Dimethoxyphenyl)acetic acid, 99%
| 93-40-3 |
|
1-Naphthaleneacetamide, 98%
| 86-86-2 |
|
Chlorosulfonyl isocyanate, 98+%
| 1189-71-5 |
|
4-Chloro-4'-Fluorobutyrophenone, 97+% (GC)
| 3874-54-2 |
|
Vitamin d2 (calciferol),99% (hplc)
| 50-14-6 |
|
Diethyl Phosphonoacetaldehyde Diethyl Acetal, Tech. 90%
| 7598-61-0 |
|
3,5-Dimethoxyacetophenone, 97%
| 39151-19-4 |
|
Palladium on Activated Carbon (5% Pd)
| |
|
Cyclododecene, Tech., Predominantly Trans
| 1501-82-2 |
|
4-Hydroxy-6-methyl-2-pyrone
| 675-10-5 |
|
Benzoyl bromide, 97%
| 618-32-6 |
|
Prostaglandin e1, 98+%
| 745-65-3 |
|
4,4'-Dimethylbenzil, 99+%
| 3457-48-5 |
|
Chrysoidin
| 532-82-1 |
|
d-Limonene
| 5989-27-5 |
|
Mitomycin C (Contains 2mg Mitomycin C and 48mg Sodium Chloride)
| 50-07-7 |
|
Butyl methacrylate/isobutyl methacrylate copolymer, high molecular
| 9011-53-4 |
|
Bis-(2-Methylallyl)Cycloocta-1,5-Diene Ruthenium(II) Complex
| 0-00-1 |
|
d-Lysergic acid hydrate, 95% *** controled product kb 11.6.87 ***
| 82-58-6 |
|
2-Bromo-1-Indanol, 99%
| 5400-80-6 |
|
Ruthenium(IV) oxide hydrate
| 32740-79-7 |
|
2-Chlorocyclohexanol, Tech., 90%
| 1561-86-0 |
|
5-Amino-2,2,4-Trimethyl-1-Cyclopentane-Methylamine, 99%, Mixture of
| 67907-32-8 |
|
2,3,4-Trimethoxybenzoic acid, 98+%
| 573-11-5 |
|
1,3-Dibromo-5,5-dimethylhydantoin, 98%
| 77-48-5 |
|
Dicumarol, 99%
| 66-76-2 |
|
Tetraphenylphosphonium Chloride 99%
| 2001-45-8 |
|
Benzo[k]fluoranthene, 99+% (tlc)
| 207-08-9 |
|
Dihexylamine, 99+% (GC)
| 143-16-8 |
|
Propargyl Alcohol, 99%
| 107-19-7 |
|
Borane-tert-butylamine complex, powder
| 7337-45-3 |
|
Tri-n-butyltin methoxide, 97%
| 1067-52-3 |
|
5-Methoxyindole-3-Carboxaldehyde, 99+%
| 10601-19-1 |
|
2,4-Dichlorophenoxyacetic acid
| 94-75-7 |
|
4-Phenylpyridine, 99%
| 939-23-1 |
|
2-Naphthalenesulfonic acid hydrate, 99%
| 120-18-3 |
|
Benzanthrone, 99%
| 82-05-3 |
|
Tripentylamine, 99%
| 621-77-2 |
|
BOC-D-Arginine Hydrochloride, Hydrate, 99%
| 114622-81-0 |
|
Phenylphosphonothioic dichloride, 97%
| 3497-00-5 |
|
3,3,5,5-Tetramethylpyrroline-N-Oxide, 98%
| 10135-38-3 |
|
1-(2-Aminoethyl)-2-Methyl-5-Nitroimidazole Dihydrochloride
| 49575-10-2 |
|
Bis(2-ethylhexyl) adipate
| 103-23-1 |
|
M-Tolyl Acetate
| 122-46-3 |
|
1,4-Dioxa-8-azaspiro(4.5)decane, 98%
| 177-11-7 |
|
DL-Homocysteinethiolactone Hydrochloride, 99%
| 6038-19-3 |
|
Ethyl Benzoate, 99+%
| 93-89-0 |
|
|